According to ChemDiv, the collaboration will focus on identifying potent hit series for a range of targets across multiple therapeutic areas. Per the agreement, Janssen will receive open-ended access to ChemDiv's discovery chemistry platform.
Ron Demuth, General Manager of ChemDiv, told us, “The goals are to expand Janssen's access to novel and unique discovery chemistry while reducing their upfront costs of accessing these resources.”
Demuth explained the companies have worked collaboratively for several years in multiple business models, including pipeline enrichment via multiple jointly-conducted integrated discovery projects aimed at validating and drugging targets for specific disease indications, compound inventory enrichment deals, medicinal chemistry projects, as well as preclinical and clinical development of Janssen candidates.
As part of the most recent collaboration, ChemDiv will receive upfront access fees, and milestones based on successful new leads and candidates developed from these resources.
The CRO is engaged with four other Pharma partners in similar business models, the first of which was initiated in 2010.
Demuth said the collaborations have been “quite productive in the sense that many new leads development candidates have resulted.”